Physician profile
Tamera Coyne-Beasley
NPI 1225055197
$154,496.00
in general payments reported to CMS, 2019-2025
11 companies · $35K in 2025
The $35K reported for 2025 was more than what 99% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,628 · 2020: $9,790 · 2021: $18K · 2022: $33K · 2023: $39K · 2024: $15K · 2025: $35K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $48K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $28K · Travel and Lodging: $11K · Food and Beverage: $2,219.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $48,100.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $27,610.18 |
| Travel and Lodging | $11,062.84 |
| Food and Beverage | $2,218.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $80,549.58 | 2019-2025 | |
| Seqirus USA INC | $25,984.52 | 2022-2023 | Flucelvax Quadrivalent |
| Glaxosmithkline, LLC. | $20,786.94 | 2019-2024 | Bexsero |
| Dynavax Technologies Corporation | $15,490.00 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $6,075.00 | 2021-2023 | |
| Pfizer International LLC | $3,330.00 | 2020 | |
| Sanofi Pasteur INC. | $2,040.00 | 2022 | |
| Novo Nordisk INC | $112.17 | 2019 | |
| Merck Sharp & Dohme LLC | $64.00 | 2019 | |
| Biogen, INC. | $45.38 | 2019 | |
| Organon LLC | $18.41 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tamera Coyne-Beasley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.